New England Research & Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.59M | Sell |
5,525
-125
| -2% | -$35.9K | 0.75% | 40 |
|
|
2025
Q1 | $1.74M | Buy |
5,650
+10
| +0.2% | +$3.08K | 0.88% | 34 |
|
|
2024
Q4 | $1.99M | Sell |
5,640
-2,080
| -27% | -$734K | 1.01% | 28 |
|
|
2024
Q3 | $2.77M | Sell |
7,720
-475
| -6% | -$170K | 1.3% | 17 |
|
|
2024
Q2 | $2.61M | Sell |
8,195
-2,235
| -21% | -$712K | 1.25% | 16 |
|
|
2024
Q1 | $2.4M | Buy |
10,430
+2,395
| +30% | +$550K | 1.18% | 24 |
|
|
2023
Q4 | $1.77M | Sell |
8,035
-470
| -6% | -$103K | 0.94% | 31 |
|
|
2023
Q3 | $1.92M | Buy |
8,505
+2,225
| +35% | +$503K | 1.09% | 24 |
|
|
2023
Q2 | $1.39M | Buy |
6,280
+715
| +13% | +$158K | 0.8% | 48 |
|
|
2023
Q1 | $1.25M | Buy |
5,565
+1,115
| +25% | +$250K | 0.73% | 49 |
|
|
2022
Q4 | $1.24M | Sell |
4,450
-1,100
| -20% | -$306K | 0.71% | 46 |
|
|
2022
Q3 | $1.16M | Buy |
+5,550
| New | +$1.16M | 0.73% | 45 |
|
|
2022
Q1 | – | Sell |
-4,675
| Closed | -$1.01M | – | 197 |
|
|
2021
Q4 | $1.01M | Sell |
4,675
-775
| -14% | -$167K | 0.49% | 66 |
|
|
2021
Q3 | $1.01M | Buy |
5,450
+4,325
| +384% | +$798K | 0.53% | 67 |
|
|
2021
Q2 | $202K | Sell |
1,125
-2,125
| -65% | -$382K | 0.1% | 169 |
|
|
2021
Q1 | $544K | Buy |
+3,250
| New | +$544K | 0.3% | 101 |
|